Grand rounds (GR), a time-honored method of disseminating clinical and research knowledge to medical audiences, showcases speakers as successful academic role models. Exposure to successful female role models, such as GR speakers, may positively affect the retention of women in academic medicine. 1, 2 In the present study, we sought to determine whether women's representation as GR speakers reflects their representation in academic medical workforces.
mural and extramural percentages were compared via a paired t test (2-sided; P < .05 was considered significant). The University of Pittsburgh Institutional Review Board exempted this study.
Results | Nine specialties met the inclusion criteria (Table) . Emergency medicine and family medicine were the only eligible specialties without 15 or more locatable calendars. Overall, women presented 20.0% to 60.3% of the total sessions (median, 28.3%). Trainee-delivered sessions displayed comparable female and male speaker representation, comprising 2.3% to 24.1% of the total sessions.
Among sessions delivered by faculty or other nontrainees, female representation ranged from 19.6% to 53.3% (median, 26.2%). Compared with national academic medical workforces, the percentages of nontrainee female speakers were uniformly significantly lower than the female composition of the resident workforces, and lower than the female composition of the faculty workforces in all specialties except obstetrics/ gynecology and surgery.
Among nontrainee speakers, extramural speakers were less likely than intramural speakers to be women (median, 22.4% vs 29.0%; P = .01) (Figure) . When total nontrainee female speaker percentages were normalized to workforce demographic female percentages, median ratios were 0.56 for medical students, 0.61 for residents, and 0.79 for faculty (instructor through full professor).
Discussion | Women's representation among academic GR speakers falls below the percentage of female medical students (46.7%) and residents (46% overall), and often falls lower than faculty (36% overall). 3 This finding suggests that audiences are not typically exposed to presenter lineups resembling their demographic gender profiles. Such trends may reflect tendencies to invite senior speakers, since academic medicine's "leaky pipeline" leaves few women among the full professor ranks. Despite longstanding female medical student enrollment near 50% and increasing numbers of women entering junior faculty positions, women still depart academic medicine more rapidly than men. 3 Because women will not constitute half of the senior faculty at existing rates, 3 it is unlikely that waiting for current trainees to ascend academic ladders will equalize gender representation at GR podiums. Speaker selections convey messages of "this is what a leader looks like," and women's visibility in prestigious academic venues may subconsciously affect women's desires to pursue academic medicine. The lower a field's female visibility, the more likely women are to consider male stereotypes necessary for success. 5 Thus, even inadvertently disproportionate showcasing of male speakers in GR may limit female trainees' identification as future academic medical practitioners and stifle female faculty's academic ambitions. With this knowledge, GR organizers may consider implementing transparent processes to highlight more female role models that are analogous to approaches championed at some conferences, such as appointing more women to speaker invitation committees. 2, 6 Representation of women at GR podiums reflects and potentially contributes to limited female retention in academic medicine. Associations between GR representation of women and retention of women in academic medicine require further exploration; future efforts can focus on showcasing successful women role models as GR speakers.
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Review of the Drug Trials Snapshots Program of the US Food and Drug Administration: Women in Cardiovascular Drug Trials
Over the last 20 years, there have been concerns that too few women and minorities are enrolled in clinical trials to provide confidence about drug safety and effectiveness. Women's advocacy groups, in particular, have called for more representation in trials of cardiovascular diseases. In 2012, the US Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA 907) was enacted and required the FDA to report on the diversity of participants in clinical trials and the extent to which safety and effectiveness data are based on demographic factors such as sex, race, and age. In response, the FDA piloted a new transparency initiative called the Drug Trials Snapshots Program. Snapshots are data posted online in a standardized format after approval of a "new molecular entity" (NME). They show who participated in the pivotal clinical trials used to approve the drug by sex, race, and age subgroups. Snapshots also provide statements on observed demographic subgroup differences in safety and efficacy. The FDA releases a Snapshot for every NME approved after January 2015 within 30 days of the approval date.
Methods | Reviewing the first year of Snapshot data from January 1, 2015, through December 31, 2015, we documented the reported number of women in cardiovascular drug trials and whether any statements of subgroup difference were made. We compared the sex-specific safety and efficacy statements in Snapshots (http://www.fda.gov/Drugs/InformationOnDrugs /ucm412998.htm) with those made in the corresponding prescribing information (PI) accessed on Drugs@FDA: FDA Approved Drug Products (http://www.accessdata.fda.gov /scripts/cder/daf/) (and also linked on the Snapshots page). 
